Amendment: SEC Form SC 13G/A filed by Arvinas Inc.
$ARVN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 5/5/2025 | $11.00 | Buy → Hold | Truist |
| 5/2/2025 | $10.00 | Buy → Hold | Jefferies |
| 5/2/2025 | Buy → Hold | TD Cowen | |
| 3/13/2025 | $70.00 → $15.00 | Buy → Neutral | Goldman |
| 3/12/2025 | $57.00 → $12.00 | Outperform → Neutral | Wedbush |
| 3/11/2025 | Outperform → Perform | Oppenheimer | |
| 12/10/2024 | $69.00 | Buy | BTIG Research |
Leerink Partners downgraded Arvinas from Outperform to Market Perform and set a new price target of $9.00
Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00
Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera (PROTAC) to demonstrate clinical benefit in patients with breast cancer – NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today with its partner Pfizer Inc. (NYSE:PFE), announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (H
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with Parkinson's disease – – Presented preclinical data from ARV-393 program demonstrating single-agent activity and favorable combinability profile – – Initiated Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology compan
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedic
SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)
8-K - ARVINAS, INC. (0001655759) (Filer)
10-Q - ARVINAS, INC. (0001655759) (Filer)
4 - ARVINAS, INC. (0001655759) (Issuer)
4 - ARVINAS, INC. (0001655759) (Issuer)
4 - ARVINAS, INC. (0001655759) (Issuer)
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with Parkinson's disease – – Presented preclinical data from ARV-393 program demonstrating single-agent activity and favorable combinability profile – – Initiated Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology compan
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedic
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t